Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020 Injection) in Patients With Refractory Generalized Myasthenia Gravis

Next Previous
Trial Profile

A Phase I Study to Evaluate BCMA-targeted Chimeric Antigen Receptor T Cell (SYS6020 Injection) in Patients With Refractory Generalized Myasthenia Gravis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SYS 6020 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CSPC ZhongQi Pharmaceutical Technology

Most Recent Events

  • 06 Aug 2025 Status changed from not yet recruiting to recruiting.
  • 22 Nov 2024 New trial record
  • 25 Oct 2024 According to a CSPC Pharmaceutical Group media release, the company has has obtained approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials of SYS6020 for the indication of myasthenia gravis (MG) in China.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top